NeuroSense Therapeutics Stock Forecast - Simple Regression
| NRSNW Stock | USD 0.34 0.00 0.00% |
The Simple Regression forecasted value of NeuroSense Therapeutics Ltd on the next trading day is expected to be 0.29 with a mean absolute deviation of 0.07 and the sum of the absolute errors of 4.02. NeuroSense Stock Forecast is based on your current time horizon.
At this time the rsi of NeuroSense Therapeutics' share price is below 20 . This indicates that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Using NeuroSense Therapeutics hype-based prediction, you can estimate the value of NeuroSense Therapeutics Ltd from the perspective of NeuroSense Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Simple Regression forecasted value of NeuroSense Therapeutics Ltd on the next trading day is expected to be 0.29 with a mean absolute deviation of 0.07 and the sum of the absolute errors of 4.02. NeuroSense Therapeutics after-hype prediction price | USD 0.44 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
NeuroSense | Build AI portfolio with NeuroSense Stock |
NeuroSense Therapeutics Additional Predictive Modules
Most predictive techniques to examine NeuroSense price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for NeuroSense using various technical indicators. When you analyze NeuroSense charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
NeuroSense Therapeutics Simple Regression Price Forecast For the 26th of January
Given 90 days horizon, the Simple Regression forecasted value of NeuroSense Therapeutics Ltd on the next trading day is expected to be 0.29 with a mean absolute deviation of 0.07, mean absolute percentage error of 0.01, and the sum of the absolute errors of 4.02.Please note that although there have been many attempts to predict NeuroSense Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that NeuroSense Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
NeuroSense Therapeutics Stock Forecast Pattern
| Backtest NeuroSense Therapeutics | NeuroSense Therapeutics Price Prediction | Buy or Sell Advice |
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of NeuroSense Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent NeuroSense Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 112.9785 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0659 |
| MAPE | Mean absolute percentage error | 0.169 |
| SAE | Sum of the absolute errors | 4.0191 |
Predictive Modules for NeuroSense Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as NeuroSense Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.NeuroSense Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of NeuroSense Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in NeuroSense Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of NeuroSense Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
NeuroSense Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting NeuroSense Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on NeuroSense Therapeutics' historical news coverage. NeuroSense Therapeutics' after-hype downside and upside margins for the prediction period are 0.02 and 20.94, respectively. We have considered NeuroSense Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
NeuroSense Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of NeuroSense Therapeutics is based on 3 months time horizon.
NeuroSense Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as NeuroSense Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NeuroSense Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with NeuroSense Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.46 | 20.50 | 0.10 | 0.26 | 3 Events / Month | 5 Events / Month | In about 3 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.34 | 0.44 | 29.41 |
|
NeuroSense Therapeutics Hype Timeline
NeuroSense Therapeutics is now traded for 0.34. The entity has historical hype elasticity of 0.1, and average elasticity to hype of competition of -0.26. NeuroSense is estimated to increase in value after the next headline, with the price projected to jump to 0.44 or above. The average volatility of media hype impact on the company the price is over 100%. The price increase on the next news is projected to be 29.41%, whereas the daily expected return is now at 1.46%. The volatility of related hype on NeuroSense Therapeutics is about 11581.92%, with the expected price after the next announcement by competition of 0.08. NeuroSense Therapeutics Ltd has accumulated 73 K in total debt. NeuroSense Therapeutics has a current ratio of 7.92, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Note, when we think about NeuroSense Therapeutics' use of debt, we should always consider it together with its cash and equity.Assuming the 90 days horizon the next estimated press release will be in about 3 days. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.NeuroSense Therapeutics Related Hype Analysis
Having access to credible news sources related to NeuroSense Therapeutics' direct competition is more important than ever and may enhance your ability to predict NeuroSense Therapeutics' future price movements. Getting to know how NeuroSense Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how NeuroSense Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| BCLI | Brainstorm Cell Therapeutics | (0.01) | 6 per month | 0.00 | (0.02) | 9.09 | (6.67) | 24.01 | |
| MTNB | Matinas BioPharma Holdings | (0.07) | 9 per month | 0.00 | (0.13) | 11.67 | (10.67) | 39.32 | |
| ADIL | Adial Pharmaceuticals | (0.01) | 8 per month | 0.00 | (0.18) | 5.56 | (6.25) | 16.67 | |
| HCWB | HCW Biologics | (0.50) | 8 per month | 0.00 | (0.20) | 13.02 | (11.97) | 41.72 | |
| CDIO | Cardio Diagnostics Holdings | (0.25) | 7 per month | 0.00 | (0.16) | 8.44 | (12.50) | 38.04 | |
| IBO | Impact BioMedical | 0.02 | 9 per month | 0.00 | (0.03) | 8.00 | (7.41) | 61.57 | |
| ACXP | Acurx Pharmaceuticals LLC | 0.08 | 5 per month | 0.00 | (0.17) | 10.84 | (9.84) | 49.19 | |
| ADXN | Addex Therapeutics | (0.85) | 8 per month | 0.00 | (0.07) | 7.92 | (7.28) | 26.68 | |
| CELZ | Creative Medical Technology | (0.16) | 10 per month | 0.00 | (0.08) | 9.31 | (11.22) | 50.90 | |
| APRE | Aprea Therapeutics | (0.02) | 10 per month | 0.00 | (0.27) | 4.40 | (8.40) | 17.87 |
NeuroSense Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NeuroSense Therapeutics stock to make a market-neutral strategy. Peer analysis of NeuroSense Therapeutics could also be used in its relative valuation, which is a method of valuing NeuroSense Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
NeuroSense Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how NeuroSense Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading NeuroSense Therapeutics shares will generate the highest return on investment. By undertsting and applying NeuroSense Therapeutics stock market strength indicators, traders can identify NeuroSense Therapeutics Ltd entry and exit signals to maximize returns.
NeuroSense Therapeutics Risk Indicators
The analysis of NeuroSense Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in NeuroSense Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting neurosense stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 13.14 | |||
| Semi Deviation | 14.77 | |||
| Standard Deviation | 19.88 | |||
| Variance | 395.15 | |||
| Downside Variance | 312.43 | |||
| Semi Variance | 218.15 | |||
| Expected Short fall | (17.89) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for NeuroSense Therapeutics
The number of cover stories for NeuroSense Therapeutics depends on current market conditions and NeuroSense Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that NeuroSense Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about NeuroSense Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
NeuroSense Therapeutics Short Properties
NeuroSense Therapeutics' future price predictability will typically decrease when NeuroSense Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of NeuroSense Therapeutics Ltd often depends not only on the future outlook of the potential NeuroSense Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NeuroSense Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 18.6 M | |
| Cash And Short Term Investments | 3.4 M |
Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.